Jacobio and Allist Pharmaceuticals Partner to Develop Glecirasib and JAB-3312 Across China
Shots:
- Allist has secured China rights (mainland China, Hong Kong, Macau, Taiwan) of glecirasib & JAB-3312 from Jacobio, handling its development & commercialization
- Jacobio will get ~$28.12M (~RMB200M), incl. $21.09M (RMB150M) upfront & $7.03M (RMB50M) for R&D expenses, ~$98.44M (~RMB700M) development, regulatory & commercial milestones plus net-sales-based tiered double-digit royalties (20% on JAB-3312 sales)
- Additionally, P-II study of glecirasib alone as 2L treatment of KRAS G12C mutant NSCLC showed cORR: 47.9% (CR in 4), >50% tumor reduction in 36, DCR: 86.3%, mPFS: 8.2mos. & mOS: 13.6mos.; NDA received priority review. First patient has been dosed in P-III study of glecirasib & JAB-3312 vs SoC in front-line KRAS G12C mutant NSCLC
Ref: Jacobio Pharma | Image: Jacobio & Allist Pharmaceuticals
Related News:- Jacobio Pharma Reports Data from the P-II Study of Glecirasib for Treating Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
